Sherbrooke, Canada Clinical Trials
A listing of Sherbrooke, Canada clinical trials actively recruiting patients volunteers.
Found 101 clinical trials
Sickle Cell Disease Study: Own Your Health, Share Your Story with PicnicHealth
Get all of your medical records in one secure account and contribute to important real-world Sickle Cell research with PicnicHealth. If you have Sickle Cell, you get $50 for signing up and a free lifetime access to your medical records. Visit this link to learn more and sign up. …
- 11 views
- 04 Aug, 2022
- 1 location
- Online study
Caregiver-Provided Life Review for Persons with Dementia
This study, Caregiver-Provided Life Review (C-PLR) is created based on Life Review therapy. It is for persons living with early-stage dementia along with mild depressive symptoms who are 65 years or older, community-dwellers or the residents of senior housing, independent or assisted living facilities conducted by their family members (18 …
- 547 views
- 09 Aug, 2022
- 1 location
- Online study
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept …
- 23119 views
- 01 Jul, 2022
- +9 other locations
Objective, Passive Assessment of LRRK2 Carriers (OPAL)
This study is currently only open to active participants in the University of Rochester’s VALOR-PD study. The goal of this project is to identify objective, sensitive, and convenient measures for assessing early signs of Parkinson's disease in an at-risk population at home. We will do so by using a wireless …
- 8 views
- 12 May, 2022
- 1 location
- Online study
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
This study aims to define the efficacy and safety of inebilizumab for the prevention of flare of IgG4-related disease (IgG4-RD).
- 0 views
- 23 Apr, 2022
- +69 other locations
Fluids in Septic Shock (FISSH) (FISSH)
Despite evidence of the physiologic benefits and possible lower mortality associated with low chloride solutions, normal saline remains the most wildly used fluid in the world. Given uncertainty about the impact of lower chloride versus higher chloride solutions on mortality, it is unlikely that clinical practice will change without new …
- 12 views
- 07 Jul, 2022
- +16 other locations
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) (phaethuSA)
Primary Objective: To evaluate the therapeutic efficacy of one dose level of SAR441344 versus placebo over 12 weeks in adult patients with primary Sjögren's syndrome (pSjS), assessed by the change of the European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) Secondary Objectives: To evaluate the therapeutic efficacy …
- 123 views
- 15 Jul, 2022
- +31 other locations
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06)
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
- 215 views
- 15 Jul, 2022
- +230 other locations
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC
Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards
- 144 views
- 25 Jul, 2022
- +24 other locations
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
An investigation of the ability of Tildacerfont to reduce supraphysiologic glucocorticoid dosing in classic CAH subjects up to 76 weeks of treatment. Optional open label extension up to 240 weeks.
- 10 views
- 25 Jul, 2022
- +52 other locations